Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Eur Urol. 2020 Apr 19;78(5):671–679. doi: 10.1016/j.eururo.2020.03.024

Fig. 1 –

Fig. 1 –

Landscape of somatic CDK12 mutations across 25 cancer types in the MSK-IMPACT cohort. (A) Somatic CDK12 alteration prevalence (left panel), proportion of kinase domain mutations among all missense mutations (middle panel), and proportion of cases with >1 CDK12 mutation in an individual tumor (right panel) across 26743 tumors from 25 different cancer types. CDK12 is significantly mutated in prostate and ovarian cancer only. * Significantly mutated according to MutSigCV. (B) Distribution of missense (upper green lollipop) and truncating mutations (lower black lollipop) in CDK12 in prostate cancer. (C) Prevalence and type of biallelic inactivation of CDK12 in prostate and ovarian cancer. (D) Prevalence of CDK12 clonal mutations compared to all other mutations in prostate and ovarian cancer. (E) CDK12 alterations in matched tumors in the prostate CDK12 alteration cohort, including localized primaries and later metastases and other matched tumors from the same patients. LOH = loss of heterozygosity; NA = not evaluable.